Skip to content
WealthTicker

Compare

NAVs as of 20 Aug 2026

Invesco India Balanced Advantage FundDirect · IDCW1 of 4 funds

Add a second fund to compare. Until then every figure below is shown against the Dynamic Asset Allocation or Balanced Advantage median (38 funds), which is the only comparison one fund can support.

Growth of ₹100 (rebased over the selected window)

Common period 02 Jan 201320 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 50 history starts 18 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.

View as table
Growth of ₹100, sampled across the common period
DateInvesco India Balanced Advantage Fund
02 Jan 2013₹100.00
21 Feb 2014₹113.46
12 Apr 2015₹145.88
31 May 2016₹129.31
19 Jul 2017₹150.07
07 Sep 2018₹146.09
27 Oct 2019₹133.94
15 Dec 2020₹136.61
03 Feb 2022₹148.26
25 Mar 2023₹139.94
12 May 2024₹171.49
01 Jul 2025₹181.04
20 Aug 2026₹159.04
Invesco India Balanced Advantage Fund compared on return, risk, benchmark-relative, cost and portfolio metrics, against the Dynamic Asset Allocation or Balanced Advantage median.
Metric
Invesco · Direct · IDCW
NAV ₹21.98
High risk
★☆☆☆☆
Category median
Dynamic Asset Allocation or Balanced Advantage · 38 funds
-9.92%+0.11%
+1.51%+6.19%
+1.58%+5.02%
+1.37%+4.37%
+3.46%+5.50%
-0.01%
+3.47%+7.11%
+2.76%+5.14%
+3.21%+4.90%
Risk
8.49%9.25%
-0.59-0.05
-0.76-0.07
-37.56%-19.52%
Nifty 50
-6.01%-1.49%
0.620.63
52.8%61.6%
73.4%55.6%
1.14%1.04%
₹1,020Cr₹2,137Cr
Up to 0.25%
None
₹100
₹1.00K
101%258%
Krishna Venkat Cheemalapati · 1.5y
02 Jan 2013
37
39.5%
13.6%

Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.